Skip to main content
Premium Trial:

Request an Annual Quote

14M Genomics Shutters Business as Funding Disappears

NEW YORK (GenomeWeb) – Cancer Diagnostics startup 14M Genomics has announced the end of its business.

In a statement posted to its website, the firm said that Syncona, its sole investor, has declined to provide further funding.

"Having carefully considered the options available, the Board of 14M Genomics has decided to effect an orderly close down of the business operations," Chairman Andrew Sandham said.

Hinxton, UK-based 14M Genomics was a Wellcome Trust Sanger Institute spin out focused on cancer sequencing and analysis. The firm was building a web portal for clinical genomic data to help clinicians with patient stratification in drug trials as well as with diagnosis, prognosis and treatment decisions.

In December 2014, 14M Genomics received £12.5 million ($19.7 million) in equity financing from investment firm Syncona Partners to develop oncology diagnostic and treatment services.

The firm had successfully signed collaboration agreements for use of its genomic profiling tools with the European Organisation for Treatment of Cancer and the Haematological Malignancy Research Network.

The firm added that the decision from Syncona came after a review of funding priorities within its investment portfolio.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.